Intrathecal and Intracerebroventricular Drug Delivery

Migration, Crosslink

📖

Intrathecal and Intracerebroventricular Drug Delivery

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-intrathecal-drug-deliv

📖 Wiki Page

therapeutic1935 wordssynced 2026-04-02

Intrathecal and Intracerebroventricular Drug Delivery

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Intrathecal and Intracerebroventricular Drug Delivery</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">Nusinersen</td>
<td>Spinal Muscular Atrophy</td>
</tr>
<tr>
<td class="label">Inotersen</td>
<td>hATTR Polyneuropathy</td>
</tr>
<tr>
<td class="label">Tominersen</td>
<td>Huntington's Disease</td>
</tr>
<tr>
<td class="label">IONIS-HTTRx</td>
<td>Huntington's Disease</td>
</tr>
<tr>
<td class="label">Enzyme</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">Idursulfase</td>
<td>Hunter Syndrome (MPS II)</td>
</tr>
<tr>
<td class="label">Arylsulfatase A</td>
<td>Metachromatic Leukodystrophy</td>
</tr>
<tr>
<td class="label">Hexosaminidase A</td>
<td>Tay-Sachs</td>
</tr>
</table>

Intrathecal And Intracerebroventricular Drug Delivery is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

Intrathecal and Intracerebroventricular Drug Delivery

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Intrathecal and Intracerebroventricular Drug Delivery</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">Nusinersen</td>
<td>Spinal Muscular Atrophy</td>
</tr>
<tr>
<td class="label">Inotersen</td>
<td>hATTR Polyneuropathy</td>
</tr>
<tr>
<td class="label">Tominersen</td>
<td>Huntington's Disease</td>
</tr>
<tr>
<td class="label">IONIS-HTTRx</td>
<td>Huntington's Disease</td>
</tr>
<tr>
<td class="label">Enzyme</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">Idursulfase</td>
<td>Hunter Syndrome (MPS II)</td>
</tr>
<tr>
<td class="label">Arylsulfatase A</td>
<td>Metachromatic Leukodystrophy</td>
</tr>
<tr>
<td class="label">Hexosaminidase A</td>
<td>Tay-Sachs</td>
</tr>
</table>

Intrathecal And Intracerebroventricular Drug Delivery is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Intrathecal (IT) and intracerebroventricular (ICV) drug delivery are targeted delivery methods that bypass the blood-brain barrier (BBB) by placing therapeutic agents directly into the cerebrospinal fluid (CSF) spaces.[@rigo2020][@geary2015] These approaches are essential for treating neurological disorders where systemically administered drugs cannot achieve therapeutic concentrations in the central nervous system (CNS). Intrathecal delivery involves injection into the subarachnoid space surrounding the spinal cord, while intracerebroventricular delivery involves injection directly into the cerebral ventricles.[@rigo2020]

These delivery methods have become increasingly important in neurodegenerative disease therapeutics, particularly for large molecule drugs (antisense oligonucleotides, proteins, antibodies), gene therapies, and small molecules that do not cross the [BBB](/entities/blood-brain-barrier) effectively.[@bennett2019] The ability to deliver drugs directly to the CSF dramatically increases CNS exposure while reducing peripheral exposure and associated toxicities.

Physiological Considerations

Cerebrospinal Fluid Dynamics

The CSF system consists of approximately 150 mL of fluid in adults, distributed among the cerebral ventricles (approximately 25 mL), the cranial subarachnoid space (approximately 100 mL), and the spinal subarachnoid space (approximately 25 mL).[@sakka2011] CSF is produced by the choroid plexus at a rate of approximately 500 mL per day, circulating through the ventricular system and subarachnoid spaces before being absorbed into the venous system through arachnoid villi.

Understanding CSF dynamics is critical for drug delivery:

Bulk flow: CSF circulates from production sites to absorption sites
Pulsatile movement: Cardiac and respiratory cycles drive CSF movement
Diffusion: Drug distribution depends on molecular size gradients and concentration
Convection: Active transport mechanisms can enhance distribution[@sakka2011]

Blood-CSF Barrier

The blood-CSF barrier (BCSFB) consists of choroid plexus epithelial cells connected by tight junctions, separating the CSF from blood capillaries.[@geary2015] Unlike the BBB, the BCSFB has limited expression of efflux transporters, but still restricts passage of most large molecules and many small molecules.

Intrathecal and ICV delivery bypass both the BBB and BCSFB, achieving direct access to the CNS extracellular space. However, distribution from the CSF to brain parenchyma remains limited by:

The pia mater: Covers the brain and spinal cord surface
Virchow-Robin spaces: Perivascular compartments that may facilitate some distribution
White matter diffusion: Relatively slow compared to gray matter[@geary2015]

Distribution Limitations

Drug distribution from the CSF to CNS tissue is influenced by:

Molecular size: Smaller molecules diffuse more readily

Lipophilicity: More lipophilic drugs penetrate brain tissue better

Charge: Ionized species have reduced penetration

Concentration gradients: Higher doses create larger driving forces

Brain region: Some areas (e.g., periventricular) receive higher exposure[@rigo2020]

Delivery Methods

Lumbar Puncture

The most common method for intrathecal delivery involves lumbar puncture (LP), typically performed at the L3-L4 or L4-L5 vertebral level to avoid spinal cord injury.[@evans2018]

Procedure:

Patient positioned in lateral decubitus or sitting position
Local anesthetic administered
Needle advanced into subarachnoid space
CSF obtained for pressure/analysis (if needed)
Drug injected slowly

Advantages:

Relatively simple procedure
Can be performed in outpatient setting
Lower risk than implanted systems
Repeatable

Limitations:

Variable CSF access
Risk of post-dural puncture headache
Multiple injections required for chronic therapy
Limited reach to rostral brain regions[@evans2018]

Intrathecal Catheter and Pump Implantation

For chronic delivery, implanted systems provide reliable access:

Components:

Intrathecal catheter (silicone or polyurethane)
Subcutaneous pump/reservoir
Programmable controller

Pump types:

Continuous infusion pumps: Deliver constant drug infusion

Programmable pumps: Allow variable dosing schedules

Patient-controlled analgesia (PCA): Allow patient-initiated dosing

Applications:

Long-term analgesic delivery (baclofen, opioids)
Chronic ASO therapy
Enzyme replacement therapy[@de2020]

Intracerebroventricular Delivery

ICV delivery involves access to the cerebral ventricles, typically the lateral ventricle:

Methods:

External ventricular drain (EVD): Temporary catheter

Ommaya reservoir: Subcutaneous reservoir with intraventricular catheter

Implanted ventricular catheter: Permanent access

Advantages over intrathecal:

Direct access to CSF production/absorption sites
Better distribution to periventricular brain regions
Lower risk of spinal complications

Limitations:

More invasive procedure
Higher infection risk
Requires neurosurgical intervention[@morrison2014]

Convection-Enhanced Delivery

Convection-enhanced delivery (CED) uses hydrostatic pressure to drive drug directly into brain tissue, bypassing CSF altogether:[@bobo1994]

Microcatheters deliver infusate under pressure
Creates bulk flow through extracellular space
Enables targeted delivery to specific brain regions
Reduces systemic exposure

CED is particularly relevant for:

Convection-enhanced delivery of macromolecules
Targeted delivery to tumors
Gene therapy vectors[@bobo1994]

Therapeutic Applications

Antisense Oligonucleotide (ASO) Therapy

ASOs are short synthetic oligonucleotides that modulate RNA splicing, translation, or degradation. Several ASOs have received FDA approval for neurological diseases, all administered intrathecally:[@bennett2019]

Dosing: Typically loading dose followed by maintenance doses every 1-3 months

Distribution: Achieves widespread CNS distribution within weeks of repeated dosing[@evers2015]

Gene Therapy

Intrathecal and ICV routes are being developed for CNS gene therapy:

AAV vectors: Adeno-associated viruses can be delivered intrathecally to achieve broad CNS transduction:[@samaranch2014]

AAV9: Transduces [neurons](/entities/neurons) and glia
AAVrh.10: Alternative serotype
Self-complementary vectors: Faster onset

Challenges:

Immune response to viral capsid
Limited distribution beyond injection site
Dorsal root ganglion toxicity (some serotypes)[@samaranch2014]

Enzyme Replacement Therapy

For lysosomal storage diseases affecting the CNS:

Small Molecule Delivery

Some small molecules that poorly cross the BBB may be delivered intrathecally:

Ziconotide: Peptide toxin for pain (IT pump)
Baclofen: GABA-B agonist for spasticity (IT pump)
Chemotherapy: For leptomeningeal carcinomatosis

Monoclonal Antibodies

Therapeutic antibodies are typically too large to cross the BBB. Intrathecal delivery is being explored for:

Anti-amyloid antibodies: AD immunotherapy
Anti-[tau](/proteins/tau) antibodies: [Tau](/proteins/tau)-targeted therapy
Anti-[alpha-synuclein](/proteins/alpha-synuclein) antibodies: PD therapy

Early clinical trials show limited efficacy, likely due to insufficient distribution from CSF to brain parenchyma.[@sevigny2016]

Pharmacokinetics and Pharmacodynamics

CSF Pharmacokinetics

Key parameters for intrathecal drug delivery:

Half-life in CSF: Typically 3-6 hours for small molecules, longer for ASOs

Clearance: Primarily through arachnoid villi to venous blood

Distribution: Dependent on molecular size, charge, lipophilicity

Protein binding: Lower in CSF than plasma[@rigo2020]

Systemic Exposure

Although intrathecal delivery bypasses the BBB, systemic exposure still occurs:

Venous reabsorption: Drug diffuses from CSF to blood via arachnoid villi
Lymphatic drainage: Some drug enters lymphatic system
Peripheral target effects: Some drugs have peripheral targets

Minimizing systemic exposure is important for drugs with peripheral toxicity.

Dose Selection

Intrathecal doses are typically 1-10% of equivalent intravenous doses due to:

Higher CNS bioavailability
Reduced peripheral exposure
Direct targeting of CNS disease sites[@rigo2020]

Adverse Effects and Complications

Lumbar Puncture:

Post-dural puncture headache (5-30%)
Back pain (10-20%)
Bleeding (rare)
Infection (rare, meningitis)
Nerve root irritation[@evans2018]

Implanted Systems:

Surgical site infection (2-5%)
Catheter malposition
Pump malfunction
CSF leak[@de2020]

ASOs:

Headache (common)
Nausea/vomiting
Elevated CSF protein
Thrombocytopenia
Renal toxicity (some compounds)[@evers2015]

Gene Therapy:

Immune response to vector
[Neuroinflammation](/mechanisms/neuroinflammation)
Dorsal root ganglion toxicity
Hepatotoxicity[@samaranch2014]

Long-Term Considerations

Development of anti-drug antibodies
CSF protein elevation
Meningeal inflammation
Progressive neurological deficits (unrelated to drug)

Future Directions

Enhanced Distribution

Research focuses on improving drug distribution from CSF to brain:

Focused ultrasound: Temporarily opens BBB to enhance distribution

Novel formulations: Encapsulated or conjugated drugs

Convection-enhanced delivery: Direct parenchymal infusion

Repeated dosing: Maintains CSF concentrations

Alternative Routes

Other CNS delivery approaches under development:

Nasal delivery: Olfactory pathway to brain
Ocular delivery: Retrograde transport along optic nerve
Peripheral nerve delivery: Transport to CNS via axons
BBB modulation: Transient opening with drugs or devices

Personalized Dosing

Future approaches may include:

CSF drug level monitoring
Pharmacogenetic optimization
MRI-guided delivery
Real-time feedback control[@pardridge2021]

Clinical Considerations

Patient Selection

Ideal candidates for intrathecal delivery:

Confirmed CNS disease with limited systemic therapy options
Adequate CSF access
Ability to tolerate procedures
No active infection
Informed consent

Monitoring

Key monitoring parameters:

CSF cell count and protein (baseline and follow-up)
Systemic blood counts and chemistry
Neurological examination
Imaging (if indicated)
Therapeutic drug levels (if applicable)

Multidisciplinary Care

Successful intrathecal therapy requires:

Neurology/neurosurgery expertise
Pharmacy support
Nursing education
Rehabilitation services
Patient and family education

Summary

Intrathecal and intracerebroventricular drug delivery provide essential routes for treating CNS diseases that cannot be effectively addressed with systemic therapy. These approaches are particularly important for large molecule drugs (ASOs, proteins, antibodies), gene therapies, and select small molecules. While delivery methods continue to improve, challenges remain in achieving uniform drug distribution throughout the CNS. Understanding CSF dynamics, selecting appropriate delivery methods, and managing complications are essential for optimal clinical outcomes.

Background

The study of Intrathecal And Intracerebroventricular Drug Delivery has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/) - Gene database
[UniProt](https://www.uniprot.org/) - Protein database

References

[Rigo et al., Antisense oligonucleotide-based therapies for diseases of the nervous system (2020) (2020)](https://doi.org/10.1038/s41573-020-0070-0)

[Geary et al., Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides (2015) (2015)](https://doi.org/10.1016/j.addr.2015.01.008)

[Bennett et al., RNA-targeted therapeutics for neurological disease (2019) (2019)](https://doi.org/10.1016/j.drudis.2019.02.003)

[Sakka et al., Physiology and pathophysiology of the cerebrospinal fluid (2011) (2011)](https://doi.org/10.1016/j.jneurol.2011.07.004)

[Unknown, Evans, Lumbar puncture technique (2018) (2018)](https://doi.org/10.1016/j.neurologia.2017.12.001)

[De Andres et al., Intrathecal drug delivery systems (2020) (2020)](https://doi.org/10.3390/ijms21010304)

[Morrison et al., Intracerebroventricular drug delivery (2014) (2014)](https://doi.org/10.1016/j.neuropharm.2013.12.018)

[Bobo et al., Convection-enhanced delivery (1994) (1994)](https://doi.org/10.1073/pnas.91.6.2076)

[Evers et al., Target engagement with antisense oligonucleotides (2015) (2015)](https://doi.org/10.1016/j.tips.2015.02.001)

[Samaranch et al., AAV9-mediated CNS gene therapy (2014) (2014)](https://doi.org/10.1016/j.ymthe.2014.11.017)

[Sevigny et al., Antibody therapy for Alzheimer's disease (2016) (2016)](https://doi.org/10.1038/nature17811)

[Unknown, Pardridge, Drug delivery to the brain (2021) (2021)](https://doi.org/10.1016/j.drudis.2021.01.015)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
[Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery](/hypothesis/h-d78123d1) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: RAB27A/LAMP2B
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-intrathecal-drug-delivery

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-intrathecal-drug-delivery
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-16b8705ec7fa
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-intrathecal-drug-delivery'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

474

Outgoing

537

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Intrathecal and Intracerebroventricular Drug Delivery

Intrathecal and Intracerebroventricular Drug Delivery

Introduction

Overview

Intrathecal and Intracerebroventricular Drug Delivery

Introduction

Overview

Physiological Considerations

Cerebrospinal Fluid Dynamics

Blood-CSF Barrier

Distribution Limitations

Delivery Methods

Lumbar Puncture

Intrathecal Catheter and Pump Implantation

Intracerebroventricular Delivery

Convection-Enhanced Delivery

Therapeutic Applications

Antisense Oligonucleotide (ASO) Therapy

Gene Therapy

Enzyme Replacement Therapy

Small Molecule Delivery

Monoclonal Antibodies

Pharmacokinetics and Pharmacodynamics

CSF Pharmacokinetics

Systemic Exposure

Dose Selection

Adverse Effects and Complications

Procedure-Related Complications

Drug-Related Adverse Effects

Long-Term Considerations

Future Directions

Enhanced Distribution

Alternative Routes

Personalized Dosing

Clinical Considerations

Patient Selection

Monitoring

Multidisciplinary Care

Summary

Background

See Also

External Links

References

Related Hypotheses

💬 Discussion